Phase II study on safety and efficacy of NMS-01940153E, an MPS1 inhibitor with first-inclass potential, in adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with systemic therapy.

L. Rimassa, M. Reig, S. Damian, D. Roberti, S. Maruzzelli, F. Gasparri, P. Ghioni, M.T. De Pietro, T. Pressiani, M. Sanduzzi Zamparelli, M. Duca, A. Montagnoli, A. Galvani, E. Ardini, A. Isacchi, C. Davite, P. Crivori, L. Mahnke
2023 ASCO Annual Meeting; June 2-6, 2023; at Chicago, IL.

–Slide deck

–Abstract TPS4185
Journal of Clinical Oncology Volume 41, Number 16_suppl